Overview

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fosamprenavir
HIV Protease Inhibitors
Lopinavir
Protease Inhibitors
Ritonavir